Three biosimilars are recommended to PBS

Australia’s Pharmaceutical Benefit Advisory Committee (PBAC) has recommended ‘a-flagging’, or marking as equivalent and substitutable at the point of dispensing, two biosimilars of Humira (adalimumab) and one of Lantus (insulin glargine).